ALGS - Company ID 0001799448
The table below shows Aligos Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$23.13M | -$20.91M | -$22.75M | -$22.39M | -$20.43M | -$29.80M |
| Capital expenditure | - | - | - | $7.00K | $515.00K | $307.00K |
| Investing cash flow | $34.93M | -$44.07M | -$88.64M | $19.99M | -$60.40M | $9.69M |
| Dividends paid | - | - | - | - |
Aligos Therapeutics, Inc. reported operating cash flow of -$82.50M for fiscal year 2025. That is down 2.2% from -$80.74M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$46.77M (FY 2019) to -$82.50M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$62.00K | $101.74M | -$19.00K | -$1.00K | -$21.00K | $78.00K |